易明医药(002826) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥158,204,489.91, representing a 64.65% increase compared to ¥96,087,140.09 in the same period last year[9] - Net profit attributable to shareholders decreased by 11.89% to ¥5,259,104.57 from ¥5,968,919.24 year-on-year[9] - Revenue for Q1 2021 reached ¥158.20 million, an increase of 64.65% compared to ¥96.09 million in Q1 2020[17] - Net profit for Q1 2021 was CNY 5.26 million, a decrease of 11.9% from CNY 5.97 million in Q1 2020[40] - The net profit for the current period was ¥1,108,475.93, compared to a net loss of ¥2,553,737.01 in the previous period, marking a turnaround[43] - The total comprehensive income for the current period was ¥1,108,475.93, compared to a loss of ¥2,553,737.01 in the previous period[44] Cash Flow - The net cash flow from operating activities improved by 99.44%, reaching -¥9,808,758.10 compared to -¥13,919,475.18 in the previous year[9] - The company reported a cash inflow from operating activities of ¥244,581,040.38, an increase from ¥175,601,844.94 in the previous period[46] - The net cash flow from operating activities was negative at -¥9,808,758.10, an improvement from -¥13,919,475.18 in the previous period[46] - In Q1 2021, the net cash flow from operating activities was -CNY 40,533,386.53, compared to -CNY 33,969,541.34 in Q1 2020, indicating a decline in cash flow[49] - The company reported a total cash outflow from operating activities of CNY 278,392,381.63 in Q1 2021, an increase of 59.5% compared to CNY 174,713,027.43 in Q1 2020[49] Assets and Liabilities - The total assets at the end of the reporting period were ¥876,006,443.91, a decrease of 3.53% from ¥908,087,426.76 at the end of the previous year[9] - The company's total assets as of March 31, 2021, amounted to CNY 701.56 million, down from CNY 708.08 million at the end of 2020[36] - The company's current assets decreased from ¥450,252,514.19 at the end of 2020 to ¥422,382,680.95, representing a decline of about 6.2%[31][32] - Total liabilities decreased from ¥220,940,937.86 to ¥183,047,976.21, a reduction of about 17.2%[33][34] - The total liabilities decreased to CNY 117.91 million from CNY 126.09 million at the end of 2020, a reduction of 6.5%[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,136[13] - The largest shareholder, Gao Fan, holds 26.46% of the shares, amounting to 50,744,682 shares, with a portion pledged[13] - The company's equity attributable to shareholders increased from ¥687,146,488.90 to ¥692,958,467.70, reflecting a growth of approximately 0.6%[34] Research and Development - R&D expenses surged by 741.06% to ¥5.05 million, up from ¥0.60 million in Q1 2020, indicating a significant increase in investment in innovation[17] - Research and development expenses decreased to ¥25,259.60 from ¥151,691.67, indicating a reduction in investment in this area[42] Compliance and Governance - The company reported no non-compliance with external guarantees during the reporting period[26] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[27] - The company did not engage in any research, communication, or interview activities during the reporting period[28] Financial Adjustments - The company adopted new leasing standards starting from January 1, 2021, which resulted in adjustments to the financial statements without significant impact on financial status or cash flows[53] - The company adopted the new leasing standards starting from Q1 2021, with no significant impact on financial status, operating results, or cash flow[56]